Xavier Bosch

Cargo

Emeritus researcher at the Catalan Institute of Oncology (ICO), senior researcher at the Bellvitge Biomedical Research Institute (IDIBELL) and lecturer in the Faculty of Health Sciences at the Universitat Oberta de Catalunya (UOC)

Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), Open University of Catalonia (UOC)

Topics

vaccines, cancer, HPV

Reaction to study examining effectiveness of papillomavirus vaccine in the United States

vaccines

Reaction to study examining effectiveness of papillomavirus vaccine in the United States

SMC Spain

In the United States, the human papillomavirus vaccine began to be recommended in 2006 for girls aged 9-26 years. A study published in the journal JAMA Health Forum concludes that the campaign significantly reduced the risk of HPV infection in vaccinated women. In addition, herd immunity reduced the likelihood of infection in unvaccinated women.